A revised response to Richard Horowitz’s access-to-care claim, focused on evidence, comparable populations and the limits of personal experience.
Why proposed Morgellons criteria, clinician-observed filaments, associated symptoms and diagnostic validation must be described separately.
A comparison of named Lyme disease guidelines, their persistent-symptom recommendations, evidence grades and limits for Morgellons interpretation.
